Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 12/2014

01-12-2014 | Systematic Review

Drug-Induced Cerebellar Ataxia: A Systematic Review

Authors: J. van Gaalen, F. G. Kerstens, R. P. P. W. M. Maas, L. Härmark, B. P. C. van de Warrenburg

Published in: CNS Drugs | Issue 12/2014

Login to get access

Abstract

Background and Objectives

Cerebellar ataxia can be induced by a large number of drugs. We here conducted a systemic review of the drugs that can lead to cerebellar ataxia as an adverse drug reaction (ADR).

Methods

We performed a systematic literature search in Pubmed (1966 to January 2014) and EMBASE (1988 to January 2014) to identify all of the drugs that can have ataxia as an ADR and to assess the frequency of drug-induced ataxia for individual drugs. Furthermore, we collected reports of drug-induced ataxia over the past 20 years in the Netherlands by querying a national register of ADRs.

Results

Drug-induced ataxia was reported in association with 93 individual drugs (57 from the literature, 36 from the Dutch registry). The most common groups were antiepileptic drugs, benzodiazepines, and antineoplastics. For some, the number needed to harm was below 10. Ataxia was commonly reversible, but persistent symptoms were described with lithium and certain antineoplastics.

Conclusions

It is important to be aware of the possibility that ataxia might be drug-induced, and for some drugs the relative frequency of this particular ADR is high. In most patients, symptoms occur within days or weeks after the introduction of a new drug or an increase in dose. In general, ataxia tends to disappear after discontinuation of the drug, but chronic ataxia has been described for some drugs.
Appendix
Available only for authorised users
Literature
1.
van de Warrenburg BP, van Gaalen J, Boesch S, Burgunder JM, Durr A, Giunti P, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014;21(4):552–62.PubMed
2.
van Gaalen J, van de Warrenburg BP. A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Pract Neurol. 2012;12(1):14–24.PubMed
3.
Baath NS, Hong J, Sattar SP. Possible carbamazepine toxicity with terbinafine. Can J Clin Pharmacol. 2006;13(2):e228–31.
4.
Beattie B, Biller J, Mehlhaus B, Murray M. Verapamil-induced carbamazepine neurotoxicity. A report of two cases. Eur Neurol. 1988;28(2):104–5.PubMed
5.
Patsalos PN, Stephenson TJ, Krishna S, Elyas AA, Lascelles PT, Wiles CM. Side-effects induced by carbamazepine-10,11-epoxide. Lancet. 1985;2(8469–70):1432.PubMed
6.
Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66(3):323–30.PubMed
7.
Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2–3):278–85.PubMed
8.
Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497–504.PubMed
9.
Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P, Group BIAIS. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120(5):281–7.PubMed
10.
The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. Epilepsy Res. 1994;18(1):67–73.
11.
Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 1994;35(4):795–801.PubMed
12.
Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Portal JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. Seizure. 1998;7(1):55–62.PubMed
13.
Beran R, Berkovic S, Black A, Danta G, Dunne J, Frasca J, et al. AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures. Epilepsia. 2001;42(10):1335–9.PubMed
14.
Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage. 2000;20(4):280–5.PubMed
15.
Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L, Bernstein P. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology. 2001;56(6):743–8.PubMed
16.
Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251(10):1260–6.PubMed
17.
Huber B, Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure. 2003;12(8):602–3.PubMed
18.
Irving G, Jensen M, Cramer M, Wu J, Chiang YK, Tark M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25(3):185–92.PubMed
19.
Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007;127(1–2):151–60.PubMed
20.
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159(16):1931–7.PubMed
21.
Morris GL 3rd. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther. 1995;17(5):891–900.PubMed
22.
Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol. 2002;22(6):584–91.PubMed
23.
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–42.PubMed
24.
Spira PJ, Beran RG. Australian gabapentin chronic daily headache G. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12):1753–9.PubMed
25.
Steinhoff BJ, Herrendorf G, Bittermann HJ, Kurth C. Isolated ataxia as an idiosyncratic side-effect under gabapentin. Seizure. 1997;6(6):503–4.PubMed
26.
van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. BMC Neurol. 2004;4:13.PubMedCentralPubMed
27.
Yamauchi T, Kaneko S, Yagi K, Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci. 2006;60(4):507–15.PubMed
28.
Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–17.PubMed
29.
Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958–67.PubMed
30.
Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443–53.PubMed
31.
Alkawi A, Kattah JC, Wyman K. Downbeat nystagmus as a result of lamotrigine toxicity. Epilepsy Res. 2005;63(2–3):85–8.PubMed
32.
Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, Black AB, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia. 1998;39(12):1329–33.PubMed
33.
Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia. 1991;32(Suppl 2):S17–21.PubMed
34.
Binnie CD, Debets RM, Engelsman M, Meijer JW, Meinardi H, Overweg J, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989;4(3):222–9.PubMed
35.
Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, de Korte RA, Meijer JW, Meinardi H, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 1986;27(3):248–54.PubMed
36.
Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand. 1996;94(4):247–52.PubMed
37.
Brodie MJ. Lamotrigine—an update. Can J Neurol Sci. 1996;23(4 Suppl 2):S6–9.PubMed
38.
Cocito L, Maffini M, Loeb C. Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res. 1994;19(2):123–7.PubMed
39.
Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999;53(8):1724–31.PubMed
40.
Herold TJ. Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. CJEM. 2006;8(5):361–4.PubMed
41.
Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 1989;30(3):356–63.PubMed
42.
Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res. 1990;7(2):136–45.PubMed
43.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.PubMedCentralPubMed
44.
Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993;43(11):2284–91.PubMed
45.
Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia. 1994;35(1):113–21.PubMed
46.
Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf. 2000;22(4):303–12.PubMed
47.
Nielsen KA, Dahl M, Tommerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 2008;13(1):127–30.PubMed
48.
Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112(12):2802–8.PubMed
49.
Sander JW, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res. 1990;6(3):221–6.PubMed
50.
Sander JW, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res. 1990;7(3):226–9.PubMed
51.
Schapel GJ, Beran RG, Vajda FJ, Berkovic SF, Mashford ML, Dunagan FM, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993;56(5):448–53.PubMedCentralPubMed
52.
Schaub JE, Williamson PJ, Barnes EW, Trewby PN. Multisystem adverse reaction to lamotrigine. Lancet. 1994;344(8920):481.PubMed
53.
Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35(2):359–67.PubMed
54.
Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34(2):312–22.PubMed
55.
Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK. Brugada-like electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol. 2010;33(5):265–7.PubMed
56.
Thome-Souza S, Freitas A, Fiore LA, Valente KD. Lamotrigine and valproate: efficacy of co-administration in a pediatric population. Pediatr Neurol. 2003;28(5):360–4.PubMed
57.
Thome-Souza S, Moreira B, Valente KD. Late adverse effects of the coadministration of valproate and lamotrigine. Pediatr Neurol. 2012;47(1):47–50.PubMed
58.
Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73(2):223–30.PubMed
59.
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236–42.PubMed
60.
Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41(12):1597–607.PubMed
61.
Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27(3):205–13.PubMed
62.
Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol. 2006;35(4):235–9.PubMed
63.
Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57(5):864–71.PubMed
64.
Abe K, Okano M, Sasaki H. Phenytoin elimination kinetics in two children with drug intoxication. Eur J Pediatr. 1980;135(1):69–71.PubMed
65.
Alioglu Z, Sari A, Velioglu SK, Ouml Zmenoglu M. Cerebellar atrophy following acute phenytoin intoxication. J Neuroradiol. 2000;27(1):52–5.PubMed
66.
Awada A, Amene P, Al Jumah M, Al Beladi K. Residual cerebellar ataxia following acute phenytoin intoxication. Revue Neurol. 1999;155(4):306–8.
67.
Baier WK, Beck U, Doose H, Klinge H, Hirsch W. Cerebellar atrophy following diphenylhydantoin intoxication. Neuropediatrics. 1984;15(2):76–81.PubMed
68.
Baier WK, Beck U, Hirsch W. CT findings following diphenylhydantoin intoxication. Pediatr Radiol. 1985;15(4):220–1.PubMed
69.
Botez MI, Gravel J, Attig E, Vezina JL. Reversible chronic cerebellar ataxia after phenytoin intoxication: possible role of cerebellum in cognitive thought. Neurology. 1985;35(8):1152–7.PubMed
70.
Cachat F, Tufro A. Phenytoin/isradipine interaction causing severe neurologic toxicity. Ann Pharmacother. 2002;36(9):1399–402.PubMed
71.
Curtis DL, Piibe R, Ellenhorn MJ, Wasserberger J, Ordog G. Phenytoin toxicity: a review of 94 cases. Vet Hum Toxicol. 1989;31(2):164–5.PubMed
72.
Dorado P, Lopez-Torres E, Penas-Lledo EM, Martinez-Anton J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013;13(4):359–61.PubMed
73.
Ertan S, Ulu MO, Hanimoglu H, Tanriverdi T, Kafadar AM, Acar ZU, et al. Phenytoin-induced parkinsonism. Singapore Med J. 2006;47(11):981–3.PubMed
74.
Gannaway DJ, Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. Br J Clin Pharmacol. 1981;12(6):833–9.PubMedCentralPubMed
75.
Garson A Jr, Kugler JD, Gillette PC, Simonelli A, McNamara DG. Control of late postoperative ventricular arrhythmias with phenytoin in young patients. Am J Cardiol. 1980;46(2):290–4.PubMed
76.
Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. Am J Cardiol. 1984;54(8):1145.PubMed
77.
Gupta V, Yadav TP, Yadav A. Phenytoin toxicity presenting as acute meningo-encephalitis in children. Neurol India. 2011;59(1):66–7.PubMed
78.
Hellden A, Bergman U, Engstrom Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlof I, et al. Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. Eur J Clin Pharmacol. 2010;66(8):791–5.PubMed
79.
Imamura T, Ejima A, Sahara M, Saito H, Tsuburaya K. Cerebellar atrophy and persistent cerebellar ataxia after acute intoxication of phenytoin. No To Shinkei Brain Nerve. 1992;44(2):149–53.
80.
Kuruvilla T, Bharucha NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia. 1997;38(4):500–2.PubMed
81.
Lindvall O, Nilsson B. Cerebellar atrophy following phenytoin intoxication. Ann Neurol. 1984;16(2):258–60.PubMed
82.
Lopez-Ariztegui N, Ochoa M, Sanchez-Migallon MJ, Nevado C, Martin M. Acute phenytoin poisoning secondary to an interaction with ticlopidine. Rev Neurol. 1998;26(154):1017–8.PubMed
83.
Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit. 2001;23(1):75–7.PubMed
84.
Murphy A, Wilbur K. Phenytoin–diazepam interaction. Ann Pharmacother. 2003;37(5):659–63.
85.
Murphy JM, Motiwala R, Devinsky O. Phenytoin intoxication. South Med J. 1991;84(10):1199–204.PubMed
86.
Robertson K, von Stempel CB, Arnold I. When less is more: a case of phenytoin toxicity. BMJ Case Rep. 2013.
87.
Sanchez-Romero A, Duran-Quintana JA, Garcia-Delgado R, Margarito-Rangel C, Poveda-Andres JL. Possible gabapentin phenytoin interaction. Rev Neurol. 2002;34(10):952–3.PubMed
88.
Sharma S, Dasroy SK. Images in clinical medicine. Gingival hyperplasia induced by phenytoin. N Engl J Med. 2000;342(5):325.PubMed
89.
Sung SF, Chiang PC, Tung HH, Ong CT. Charcoal hemoperfusion in an elderly man with life-threatening adverse reactions due to poor metabolism of phenytoin. J Formos Med Assoc Taiwan Yi Zhi. 2004;103(8):648–52.
90.
Teta D, Uldry PA, Regli F. Reversible ophthalmoplegia, cerebellar syndrome and vigilance disorders following phenytoin poisoning. Schweiz Med Wochenschr. 1990;120(41):1504–7.PubMed
91.
Wessely P, Mayr N, Binder H, Klingler D. Neurological signs in diphenylhydantoin intoxication (case reports and review; author’s transl). Wien Klin Wochenschr. 1981;93(10):315–21.
92.
Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/day for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.PubMedCentralPubMed
93.
Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45(1):20–7.PubMed
94.
Baulac M, Leon T, O’Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res. 2010;91(1):10–9.PubMed
95.
Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64(3):475–80.PubMed
96.
Choi JY, Park YM, Woo YS, Kim SU, Jung JM, Kwon DY. Perverted head-shaking and positional downbeat nystagmus in pregabalin intoxication. J Neurol Sci. 2014;337(1–2):243–4.PubMed
97.
Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274–83.PubMed
98.
Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005;46(12):1926–36.PubMed
99.
French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60(10):1631–7.
100.
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–10.PubMed
101.
Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–40.PubMed
102.
Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141–9.PubMed
103.
Biton V, Gil-Nagel A, Brodie MJ, Derossett SE, Nohria V. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Epilepsy Res. 2013;107(1–2):138–45.PubMed
104.
Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817–24.PubMed
105.
French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555–63.PubMed
106.
Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002;58(11):1680–2.PubMed
107.
Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44(1):46–53.PubMed
108.
Crawford P, Meinardi H, Brown S, Rentmeester TW, Pedersen B, Pedersen PC, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia. 2001;42(4):531–8.PubMed
109.
Vossler DG, Morris GL 3rd, Harden CL, Montouris G, Faught E, Kanner AM, et al. Tiagabine in clinical practice: effects on seizure control and behavior. Epilepsy Behav. 2013;28(2):211–6.PubMed
110.
Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37(6):539–43.PubMed
111.
Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology. 1996;46(6):1684–90.PubMed
112.
Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology. 1996;46(6):1678–83.PubMed
113.
Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia. 2000;41(Suppl 1):S66–71.PubMed
114.
Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia. 1997;38(Suppl 1):S34–6.PubMed
115.
Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 1996;37(8):763–8.PubMed
116.
Bos MJ, de Weerd AW, Hagebeuk EE. Staring episodes in children with developmental disorders: epilepsy or behaviour? Ned Tijdschr Geneeskd. 2011;155:A2473.PubMed
117.
Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure. 2008;17(6):572–5.PubMed
118.
Ellaway CJ, Bennetts B, Tuck RR, Wilcken B. Clumsiness, confusion, coma, and valproate. Lancet. 1999;353(9162):1408.PubMed
119.
Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia—revisited. Br J Psychiatry. 1987;150:542–6.
120.
Gomceli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE. Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav. 2007;10(4):583–7.PubMed
121.
Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54(1):230–2.PubMed
122.
Hommet C, Mondon K, de Toffol B, Constans T. Reversible cognitive and neurological symptoms during valproic acid therapy. J Am Geriatr Soc. 2007;55(4):628.PubMed
123.
Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41(7):909–12.PubMed
124.
Osuna MT, Burcet J, Ramio L, Ustrell X, Silva Y, Molins A. Hyperammonemic encephalopathy associated with valproate acid. Neurologia. 2003;18(6):347–50.PubMed
125.
Panda S, Radhakrishnan K. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure. J Assoc Phys India. 2004;52:746–8.
126.
127.
Rottach KG, Weiss-Brummer J, Wieland U, Schmauss M. Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy. Der Nervenarzt. 2000;71(5):401–3.PubMed
128.
Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42(6):519–22.PubMed
129.
Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM, et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002;43(2):154–9.PubMed
130.
Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur Neurol. 1984;23(2):104–12.PubMed
131.
Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin. Ital J Neurol Sci. 1992;13(9):741–7.
132.
Armour DJ, Fidler C, Wright EC, Balarajan S. Vigabatrin in adults with poorly-controlled epilepsy and learning disabilities. Seizure. 1992;1(3):157–62.PubMed
133.
Beran RG, Berkovic SF, Buchanan N, Danta G, Mackenzie R, Schapel G, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure. 1996;5(4):259–65.PubMed
134.
Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol. 1989;27(Suppl 1):95S–100S.PubMedCentralPubMed
135.
Cocito L, Maffini M, Perfumo P, Roncallo F, Loeb C. Vigabatrin in complex partial seizures: a long-term study. Epilepsy Res. 1989;3(2):160–6.PubMed
136.
Dean C, Mosier M, Penry K. Dose-response study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia. 1999;40(1):74–82.
137.
Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol. 1985;17(3):262–6.PubMed
138.
Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol. 1989;27(Suppl 1):109S–12S.PubMedCentralPubMed
139.
Matilainen R, Pitkanen A, Ruutiainen T, Mervaala E, Riekkinen P. Vigabatrin in epilepsy in mentally retarded patients. Br J Clin Pharmacol. 1989;27(Suppl 1):113S–8S.PubMedCentralPubMed
140.
Sharief MK, Sander JW, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet. 1993;342(8871):619.PubMed
141.
Tartara A, Manni R, Galimberti CA, Mumford JP, Iudice A, Perucca E. Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry. 1989;52(4):467–71.PubMedCentralPubMed
142.
Faught E, Ayala R, Montouris GG, Leppik IE. Zonisamide 922 Trial G. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774–9.PubMed
143.
Leppik IE, Willmore LJ, Homan RW, Fromm G, Oommen KJ, Penry JK, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14(2):165–73.PubMed
144.
Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45(6):610–7.PubMed
145.
Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67–73.PubMed
146.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedCentralPubMed
147.
Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin Proc. 2007;82(1):40–7.PubMed
148.
Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17(5):405–21.PubMed
149.
Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528–36.PubMed
150.
151.
Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev Med Child Neurol. 2006;48(7):612–5.PubMed
152.
Kalra V, Seth R, Mishra D, Saha NC. Clobazam in refractory childhood epilepsy. Indian J Pediatr. 2010;77(3):263–6.PubMed
153.
Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure. 2003;12(4):226–8.PubMed
154.
Rose W, Kirubakaran C, Scott JX. Intermittent clobazam therapy in febrile seizures. Indian J Pediatr. 2005;72(1):31–3.PubMed
155.
Wolf P. Acute administration of benzodiazepines as part of treatment strategies for epilepsy. CNS Neurosci Ther. 2011;17(4):214–20.PubMed
156.
Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S. Serum clonazepam concentrations in children with absence seizures. Neurology. 1975;25(3):255–8.PubMed
157.
Dixon RA, Bennett NR, Harrison MJ, Kenyon C, Thornton JA. I.v. flunitrazepam and i.v. diazepam in conservative dentistry. A cross-over trial. Br J Anaesth. 1980;52(5):517–26.PubMed
158.
Maltby JR, Hamilton RC, Phillips R. Comparison of flunitrazepam and thiopentone for induction of general anaesthesia. Can Anaesth Soc J. 1980;27(4):331–7.PubMed
159.
Jan JE, Riegl JA, Crichton JU, Dunn HG. Nitrazepam in the treatmet of epilepsy in childhood. Can Med Assoc J. 1971;104(7):571–5.PubMedCentralPubMed
160.
Coldwell SE, Awamura K, Milgrom P, Depner KS, Kaufman E, Preston KL, et al. Side effects of triazolam in children. Pediatr Dent. 1999;21(1):18–25.PubMed
161.
Raadal M, Coldwell SE, Kaakko T, Milgrom P, Weinstein P, Perkis V, et al. A randomized clinical trial of triazolam in 3- to 5-year-olds. J Dent Res. 1999;78(6):1197–203.PubMed
162.
Tweedy CM, Milgrom P, Kharasch ED, Kaakko T, Spieker M, Coldwell SE. Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. J Clin Psychopharmacol. 2001;21(3):268–72.PubMed
163.
Kerry RJ, McDermott CM, Orme JE. Bromazepam, medazepam, chlordiazepoxide in treatment of neurotic anxiety. Br J Psychiatry. 1974;124:485–6.PubMed
164.
Adityanjee. The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT). Pharmacopsychiatry. 1989;22(2):81–3.PubMed
165.
Andrade C, Gangadhar BN, Channabasavanna SM. Pathological neurotoxicity with lithium. Indian J Psychiatry. 1987;29(3):279–81.PubMedCentralPubMed
166.
Apte SN, Langston JW. Permanent neurological deficits due to lithium toxicity. Ann Neurol. 1983;13(4):453–5.PubMed
167.
Arya DK. Lithium-induced neurotoxicity at serum lithium levels within the therapeutic range. Aust NZ J Psychiatry. 1996;30(6):871–3.
168.
Blanche P, Raynaud E, Kerob D, Galezowski N. Lithium intoxication in an elderly patient after combined treatment with losartan. Eur J Clin Pharmacol. 1997;52(6):501.PubMed
169.
Cerqueira AC, Reis MC, Novis FD, Bezerra JM, Magalhaes GC, Rozenthal M, et al. Cerebellar degeneration secondary to acute lithium carbonate intoxication. Arq Neuropsiquiatr. 2008;66(3A):578–80.PubMed
170.
Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA. 1974;230(9):1283–7.PubMed
171.
Dembowski C, Rechlin T. Successful antimanic treatment and mood stabilization with lamotrigine, clozapine, and valproate in a bipolar patient after lithium-induced cerebellar deterioration. A case report. Pharmacopsychiatry. 2003;36(2):83–6.PubMed
172.
Dennison U, Clarkson M, O’Mullane J, Cassidy EM. The incidence and clinical correlates of lithium toxicity: a retrospective review. Ir J Med Sci. 2011;180(3):661–5.PubMed
173.
Donaldson IM, Cuningham J. Persisting neurologic sequelae of lithium carbonate therapy. Arch Neurol. 1983;40(12):747–51.PubMed
174.
Ferbert A, Czernik A. Persistent cerebellar syndrome following lithium poisoning. Der Nervenarzt. 1987;58(12):764–70.PubMed
175.
Green JB. Permanent neurological deficits resulting from lithium toxicity. Ann Neurol. 1984;15(1):111.PubMed
176.
Ilagan MC, Carlson D, Madden JF. Lithium toxicity: two case reports. Del Med J. 2002;74(6):263–70.PubMed
177.
Johnson GF. Lithium neurotoxicity. Aust NZ J Psychiatry. 1976;10(1):33–8.
178.
Lang EJ, Davis SM. Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels. J Clin Neurosci. 2002;9(3):308–9.PubMed
179.
Lewis DA. Unrecognized chronic lithium neurotoxic reactions. JAMA. 1983;250(15):2029–30.PubMed
180.
Manto M, Godaux E, Jacquy J, Hildebrand JG. Analysis of cerebellar dysmetria associated with lithium intoxication. Neurol Res. 1996;18(5):416–24.PubMed
181.
Nagaraja D, Taly AB, Sahu RN, Channabasavanna SM, Narayanan HS. Permanent neurological sequelae due to lithium toxicity. Clin Neurol Neurosurg. 1987;89(1):31–4.PubMed
182.
Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: three cases and review of literature. Mov Disord. 2007;22(4):570–3.PubMed
183.
Ozsoy S, Basturk M, Esel E. Cerebellar syndrome in a patient with pneumonia under lithium treatment: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1532–4.PubMed
184.
Prettyman R. Lithium neurotoxicity at subtherapeutic serum levels. Br J Psychiatry. 1994;164(1):123.PubMed
185.
Schneider JA, Mirra SS. Neuropathologic correlates of persistent neurologic deficit in lithium intoxication. Ann Neurol. 1994;36(6):928–31.PubMed
186.
Sellers J, Tyrer P, Whiteley A, Banks DC, Barer DH. Neurotoxic effects of lithium with delayed rise in serum lithium levels. Br J Psychiatry. 1982;140:623–5.PubMed
187.
Singh SV. Lithium carbonate/fluphenazine decanoate producing irreversible brain damage. Lancet. 1982;2(8292):278.PubMed
188.
Uchigata M, Tanabe H, Hasue I, Kurihara M. Peripheral neuropathy due to lithium intoxication. Ann Neurol. 1981;9(4):414.PubMed
189.
Verdoux H, Bourgeois ML. A case of lithium neurotoxicity with irreversible cerebellar syndrome. J Nerv Ment Dis. 1990;178(12):761–2.PubMed
190.
Von Hartitzsch B, Hoenich NA, Leigh RJ, Wilkinson R, Frost TH, Weddel A, et al. Permanent neurological sequelae despite haemodialysis for lithium intoxication. Br Med J. 1972;4(5843):757–9.
191.
Vredeveld CJ, Morre HH. Lithium neurotoxicity in advanced age. 2 case reports with a literature review. Der Nervenarzt. 1983;54(7):377–80.PubMed
192.
Kores B, Lader MH. Irreversible lithium neurotoxicity: an overview. Clin Neuropharmacol. 1997;20(4):283–99.PubMed
193.
Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38–49.PubMed
194.
Boesen P, Fallingborg J, Spaun E. Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy. Acta Med Scand. 1988;224(2):189–91.PubMed
195.
Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol. 1985;3(5):613–6.PubMed
196.
Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-β-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 1982;42(4):1587–94.
197.
Friedman JH, Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord. 2001;16(3):575–7.PubMed
198.
Gottlieb D, Bradstock K, Koutts J, Robertson T, Lee C, Castaldi P. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer. 1987;60(7):1439–41.PubMed
199.
Grossman L, Baker MA, Sutton DM, Deck JH. Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol. 1983;11(4):246–50.PubMed
200.
Hasle H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol. 1990;27(1):76–8.PubMed
201.
Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5(6):927–32.PubMed
202.
Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48(12):2577–82.PubMed
203.
Nand S, Messmore HL Jr, Patel R, Fisher SG, Fisher RI. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol. 1986;4(4):571–5.PubMed
204.
Salinsky MC, Levine RL, Aubuchon JP, Schutta HS. Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer. 1983;51(3):426–9.PubMed
205.
Sylvester RK, Fisher AJ, Lobell M. Cytarabine-induced cerebellar syndrome: case report and literature review. Drug Intell Clin Pharm. 1987;21(2):177–80.PubMed
206.
Winkelman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol. 1983;14(5):520–7.PubMed
207.
Yeshurun M, Marsot Dupuch K. Acute cerebellar syndrome following intermediate-dose cytarabine. Br J Haematol. 2001;113(4):846.PubMed
208.
Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, et al. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992;69(4):878–82.PubMed
209.
Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer. 1994;74(3):958–61.PubMed
210.
Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol. 1996;19(2):136–9.PubMed
211.
Kaleyias J, Faerber E, Kothare SV. Tacrolimus induced subacute cerebellar ataxia. Eur J Paediatr Neurol. 2006;10(2):86–9.PubMed
212.
Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology. 2005;64(9):1641–3.PubMed
213.
Ringelstein A, Bongs K, Sorge-Hadicke B, Berlit P. Case of inflammatory vasculopathy and encephalopathy caused by treatment with tacrolimus. Der Nervenarzt. 2005;76(4):475–8.PubMed
214.
Sokol DK, Molleston JP, Filo RS, Van Valer J, Edwards-Brown M. Tacrolimus (FK506)-induced mutism after liver transplant. Pediatr Neurol. 2003;28(2):156–8.PubMed
215.
Yamaguchi I, Ichikawa T, Nakao K, Hamasaki K, Hirano K, Eguchi S, et al. Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report. Transpl Proc. 2007;39(10):3495–7.
216.
Baz DV, Bofill JS, Nogueira JA. Irinotecan-induced dysarthria. J Natl Cancer Inst. 2001;93(18):1419–20.PubMed
217.
De Marco S, Squilloni E, Vigna L, Bertagnolio MF, Sternberg CN. Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann Oncol. 2004;15(7):1147–8.PubMed
218.
Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol. 2008;47(5):974–8.PubMed
219.
Hamberg P, Donders RC, ten Bokkel Huinink D. Central nervous system toxicity induced by irinotecan. J Natl Cancer Inst. 2006;98(3):219.PubMed
220.
Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Spinal cord and cerebellar-like syndromes associated with the use of cyclosporine in human recipients of allogeneic marrow transplants. Transpl Proc. 1985;17(2):1673–5.
221.
Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–26.PubMed
222.
Belli LS, De Carlis L, Romani F, Rondinara GF, Rimoldi P, Alberti A, et al. Dysarthria and cerebellar ataxia: late occurrence of severe neurotoxicity in a liver transplant recipient. Transpl Int. 1993;6(3):176–8.PubMed
223.
Nussbaum ES, Maxwell RE, Bitterman PB, Hertz MI, Bula W, Latchaw RE. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. J Neurosurg. 1995;82(6):1068–70.PubMed
224.
Porges Y, Blumen S, Fireman Z, Sternberg A, Zamir D. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am J Ophthalmol. 1998;126(4):607–9.PubMed
225.
Vogt DP, Lederman RJ, Carey WD, Broughan TA. Neurologic complications of liver transplantation. Transplantation. 1988;45(6):1057–61.PubMed
226.
Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-l-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol. 1988;6(6):1053–8.PubMed
227.
Atkins JN, Muss HB, Case D, Brockschmidt J, Schnell FM, O’Rourke M, et al. High-dose 24-h infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol. 1991;14(6):526–9.PubMed
228.
Gottlieb JA, Luce JK. Cerebellar ataxia with weekly 5-fluorouracil administration. Lancet. 1971;1(7690):138–9.PubMed
229.
Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci. 1988;295(2):91–3.PubMed
230.
Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer. 1989;63(3):419–22.PubMed
231.
Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep Part 1. 1964;41:15–8.
232.
Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000;34(1):35–8.PubMed
233.
Sorensen P, Andersen LJ, Hansen O, Bastholt L. Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer. Acta Oncol. 1999;38(8):1043–5.PubMed
234.
Bollen E, Lanser JB. Reversible mental deterioration and neurological disturbances with o,p′-DDD therapy. Clin Neurol Neurosurg. 1992;94(Suppl):S49–51.
235.
Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996;46(6):1596–9.PubMed
236.
Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2(8412):1116–20.PubMed
237.
Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984;34(5):669–71.PubMed
238.
Coulter DM, Edwards IR, Savage RL. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. NZ Med J. 1990;103(885):98–100.
239.
Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983;68(1):88–94.PubMed
240.
Garretto NS, Rey RD, Kohler G, Cocorullo S, Monteverde DA, Ravera BI, et al. Cerebellar syndrome caused by amiodarone. Arq Neuropsiquiatr. 1994;52(4):575–7.PubMed
241.
Greene HL, Graham EL, Werner JA, Sears GK, Gross BW, Gorham JP, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol. 1983;2(6):1114–28.PubMed
242.
Hindle JV, Ibrahim A, Ramaraj R. Ataxia caused by amiodarone in older people. Age Ageing. 2008;37(3):347–8.PubMed
243.
Krauser DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol. 2005;96(10):1463–4.PubMed
244.
McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed). 1983;287(6386):175–80.
245.
Morady F, Sauve MJ, Malone P, Shen EN, Schwartz AB, Bhandari A, et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol. 1983;52(8):975–9.PubMed
246.
Morady F, Scheinman MM, Hess DS. Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. Pacing Clin Electrophysiol. 1983;6(3 Pt 1):609–15.PubMed
247.
Onofrj M, Thomas A. Acetazolamide-responsive periodic ataxia induced by amiodarone. Mov Disord. 1999;14(2):379–81.PubMed
248.
Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009;66(7):865–9.PubMed
249.
Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med. 1987;147(5):881–4.PubMed
250.
Willis MS, Lugo AM. Amiodarone-induced neurotoxicity. Am J Health Syst Pharm. 2009;66(6):567–9.PubMed
251.
Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci. 2000;320(2):151–3.PubMed
252.
Ohara S, Hayashi R, Momoi H, Miki J, Yanagisawa N. Mexiletine in the treatment of spasmodic torticollis. Mov Disord. 1998;13(6):934–40.PubMed
253.
Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP. 1991;25(11):1168–70.PubMed
254.
Prevoznik SJ. Truncal ataxia as a complication of colistin therapy: its relation to spinal anesthesia. Anesth Analg. 1967;46(1):46–8.PubMed
255.
Chacko J, Pramod K, Sinha S, Saini J, Mahadevan A, Bharath RD, et al. Clinical, neuroimaging and pathological features of 5-nitroimidazole-induced encephalo-neuropathy in two patients: insights into possible pathogenesis. Neurol India. 2011;59(5):743–7.
256.
Graves TD, Condon M, Loucaidou M, Perry RJ. Reversible metronidazole-induced cerebellar toxicity in a multiple transplant recipient. J Neurol Sci. 2009;285(1–2):238–40.PubMed
257.
258.
Heaney CJ, Campeau NG, Lindell EP. MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity. Am J Neuroradiol. 2003;24(8):1615–7.PubMed
259.
Iqbal A, Tripathi K, Rai M, Dwivedi AN. Clinical and imaging perspective and unanswered questions in a case of metronidazole induced encephalopathy. Ann Indian Acad Neurol. 2013;16(4):569–71.PubMedCentralPubMed
260.
Kafadar I, Moustafa F, Yalcn K, Klc BA. A rare adverse effect of metronidazole: nervous system symptoms. Pediatr Emerg Care. 2013;29(6):751–2.PubMed
261.
Moosa AN, Perkins D. Neurological picture. MRI of metronidazole induced cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2010;81(7):754–5.PubMed
262.
Park KI, Chung JM, Kim JY. Metronidazole neurotoxicity: sequential neuroaxis involvement. Neurol India. 2011;59(1):104–7.PubMed
263.
Patel K, Green-Hopkins I, Lu S, Tunkel AR. Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. Int J Infect Dis. 2008;12(6):e111–4.PubMed
264.
Simonetta F, Christou F, Vandoni RE, Nierle T. Walking unsteadily: a case of acute cerebellar ataxia. BMJ Case Rep. 2013.
265.
Takase K, Santa Y, Ohta S, Yoshimura T. MRI and SPECT findings in a case of metronidazole-induced reversible acute cerebellar ataxia. Rinsho Shinkeigaku Clin Neurol. 2005;45(5):386–9.
266.
Tan CH, Chen YF, Chen CC, Chao CC, Liou HH, Hsieh ST. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry. 2011;82(4):462–5.PubMed
267.
Woodruff BK, Wijdicks EF, Marshall WF. Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med. 2002;346(1):68–9.PubMed
268.
Conners GP. Piperazine neurotoxicity: worm wobble revisited. J Emerg Med. 1995;13(3):341–3.PubMed
269.
Miller CG, Carpenter R. Neurotoxic side-effects of piperazine. Lancet. 1967;1(7495):895–6.PubMed
270.
271.
Sethi AS, Jain AM, Chawla V. Piperazine toxicity. Report of a case. Indian J Pediatr. 1968;35(244):237–8.PubMed
272.
273.
Taskapilioglu O, Seferoglu M, Kaygili E, Hakyemez B, Zarifoglu M. Reversible cerebellar toxicity during treatment with ornidazole: the first case report. J Neurol Neurosurg Psychiatry. 2010;81(3):349–50.PubMed
274.
Bendiksen A, Larsen LM. Convulsions, ataxia and hallucinations following propofol. Acta Anaesthesiol Scand. 1998;42(6):739–41.PubMed
275.
Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984;101(1):92–104.PubMed
276.
Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. Can J Neurol Sci. 2013;40(6):768–76.PubMed
277.
Zaccara G, Sisodiya SM, Giovannelli F, Walker MC, Heaney DC, Angus-Leppan H, et al. Network meta-analysis and the comparison of efficacy and tolerability of anti-epileptic drugs for treatment of refractory focal epilepsy. Br J Clin Pharmacol. 2013;76(5):827–8.PubMedCentralPubMed
Metadata
Title
Drug-Induced Cerebellar Ataxia: A Systematic Review
Authors
J. van Gaalen
F. G. Kerstens
R. P. P. W. M. Maas
L. Härmark
B. P. C. van de Warrenburg
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2014
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-014-0200-4

Other articles of this Issue 12/2014

CNS Drugs 12/2014 Go to the issue

Short Communication

A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease

Original Research Article

Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Therapy in Practice

Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians

Acknowledgement to Referees

Acknowledgement to Referees

Letter to the Editor

Comment on: “Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence”

Letter to the Editor

Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence